Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
- Sponsor
- Sun Yat-sen University
- Study ID
- NCT06533722
- Phase
- PHASE2
- Status
- Completed
Conditions
- HER2-negative Metastatic Breast Cancer
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- Gemcitabine, Vinorelbine, or Eribulin — DRUGGemcitabine Gemcitabine 1000 mg/m\^2 IV on days 1 and 8, cycled every 33 days Vinorelbine 25 mg/m\^2 IV on days 1 and 8, cycled every 33 days Eribulin 1.4 mg/m\^2 IV on days 1 and 8, cycled every 33 days
Study Details
The primary objective of this study is to explore the efficacy and safety of adaptive therapy in the treatment of post-second-line metastatic breast cancer.
Key Dates
- Start date
- Aug 4, 2024
- Status verified
- Jun 2025
- Primary completion
- Sep 20, 2024
- Completion
- May 28, 2025
Study Design
- Enrollment
- 10 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment armGemcitabine Gemcitabine 1000 mg/m\^2 IV on days 1 and 8, cycled every 33 days Vinorelbine 25 mg/m\^2 IV on days 1 and 8, cycled every 33 days Eribulin 1.4 mg/m\^2 IV on days 1 and 8, cycled every 33 days
Primary Outcome Measure
progression-free survival (PFS) [ Time Frame: 12 months ]